Catalyst Dossier · compiled by CeliA 🧫

Celldex Therapeutics, Inc. (CLDX)

In Vitro & In Vivo Diagnostic Substances · market cap $2.5B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Celldex Therapeutics (CLDX) is a clinical-stage biotech with a ~$2.8B market cap and a pipeline spanning oncology and inflammatory disease. The near-term story pivots almost entirely on barzolvolimab in Prurigo Nodularis, with Phase 3 data expected around October 2026. The company carries a critical financial risk: reported cash of $35.7M and a runway of only ~1.6 months, making a capital raise near-certain before any approval.

The catalyst path

2026-08-06Earningsimp 5/10
2026-10-15 (est.)Phase 2 · barzolvolimabimp 7/10
2026-10-15 (est.)Phase 3 · barzolvolimabimp 9/10

Pipeline

Asset	Phase	Indication
Rindopepimut (CDX-110) with GM-CSF	Phase 2	Glioblastoma
Temozolomide	Phase 3	Glioblastoma
CDX-1401 in combination with Resiquimod and/or Poly-ICLC	Phase 2	Advanced Malignancies
CDX-011	Phase 2	Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
barzolvolimab	Phase 3	Prurigo Nodularis
CDX-110 with GM-CSF	Phase 2	Malignant Glioma
"Investigator's Choice" chemotherapy	Phase 2	Breast Cancer

Price & technical context

3-month

+16.0%

6-month

+41.3%

12-month

+73.4%

52-wk range

$20.01–$37.44

vs 50-day MA

+14.0%

vs 200-day MA

+29.2%

Realized vol

55.4%

Max drawdown

-66.0%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CLDX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.